Growing adoption of GLP-1 medications among American workers is reshaping workplace health dynamics and productivity metrics. These weight loss drugs, initially developed for diabetes management, are demonstrating unexpected benefits for employee attendance and workplace performance. Companies are observing measurable improvements in sick day utilization rates as more staff members incorporate GLP-1 treatments into their wellness routines, signaling a potential shift in how organizations approach employee health benefits and metabolic wellness programs.

Summary auto-generated by AI from the original publisher's content. Editorial standards.